CytomX Therapeutics Announces New Employment Inducement Grants
16 Febrero 2022 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated oncology therapeutics, today announced that
on February 16, 2022, the Company granted nine new employees
options to purchase a total of 189,400 shares of the Company’s
common stock at an exercise price per share equal to $4.08, which
was the closing trading price on February 15, 2022, the date of the
grant.
The stock options were granted pursuant to the
Company’s 2019 Employment Inducement Incentive Plan, which was
approved by the Company’s board of directors in August 2020 under
Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to
induce new employees to enter into employment with the Company.
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company dedicated to destroying cancer
differently. By pioneering a novel class of conditionally activated
biologics, powered by its Probody® technology platform, CytomX’s
goal is to transcend the limits of current cancer treatments by
successfully leveraging therapeutic targets that were once thought
to be inaccessible. CytomX’s robust and differentiated pipeline
includes the wholly-owned praluzatamab ravtansine (CX-2009), an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD166, and CX-2029, an investigational
conditionally activated ADC directed toward CD71 co-developed with
AbbVie. These two programs are currently being evaluated in Phase 2
studies, targeting a variety of late-stage, difficult-to-treat
cancer types, including breast cancer for praluzatamab ravtansine,
and squamous non-small cell lung cancer, and head and neck squamous
cell carcinoma for CX-2029. CytomX’s clinical pipeline also
includes cancer immunotherapeutic candidates against validated
targets such as the CTLA-4-targeting Probody therapeutics,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and
our wholly-owned conditionally activated anti-PD-L1 antibody,
pacmilimab (CX-072), as well as CX-904, a conditionally activated
T-cell-engaging bispecific antibody targeting the epidermal growth
factor receptor on tumor cells and the CD3 receptor on T cells.
CX-904 is entering Phase 1 clinical evaluation and is partnered
with Amgen. In addition, CytomX has a diverse preclinical portfolio
and strategic collaborations with multiple leaders in oncology,
including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For
more information about CytomX and how it is working to make
conditionally activated treatments the new standard-of-care in the
fight against cancer, visit www.cytomx.com and follow us on
LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor Contact:Chau Cheng,
PhD MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.comDirect: (650) 273-4999
Media Contact:Bret
CoonsDirector, Corporate Communicationsbcoons@cytomx.comDirect:
(650) 528 2929
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024